We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

62 hedge funds and large institutions have $130M invested in Stemline Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,671% more call options, than puts

Call options by funds: $264K | Put options by funds: $7K

46% more capital invested

Capital invested by funds: $88.9M → $130M (+$41.1M)

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

2% more funds holding

Funds holding: 61 → 62 (+1)

Holders
62
Holders Change
+1
Holders Change %
+1.64%
% of All Funds
1.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
19
Reduced
15
Closed
8
Calls
$264K
Puts
$7K
Net Calls
+$257K
Net Calls Change
+$431K

Top Buyers

Rank Fund Capital Flow
1
VM
VHCP Management
New York
+$4.12M
2
Goldman Sachs
Goldman Sachs
New York
+$2.67M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$2.16M
4
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
+$924K
5
BFA
BlackRock Fund Advisors
California
+$801K

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$2.12M
2
VAM
Visium Asset Management
New York
-$1.87M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.24M
4
TC
TFS Capital
Pennsylvania
-$932K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$679K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$28M – – –
Franklin Resources
2
Franklin Resources
California
$16.6M – – –
TCM
3
TimesSquare Capital Management
New York
$14.3M +$565K +39,155 +5%
EAM
4
Eventide Asset Management
Massachusetts
$10.2M +$299K +20,700 +4%
Goldman Sachs
5
Goldman Sachs
New York
$8.21M +$2.67M +185,094 +62%
VM
6
VHCP Management
New York
$6.08M +$4.12M +285,400 +402%
BBA
7
Baker Bros. Advisors
New York
$5.78M – – –
BFA
8
BlackRock Fund Advisors
California
$5.62M +$801K +55,556 +20%
Vanguard Group
9
Vanguard Group
Pennsylvania
$5.27M +$122K +8,453 +3%
State Street
10
State Street
Massachusetts
$3.09M +$2.6K +180 +0.1%
Millennium Management
11
Millennium Management
New York
$2.79M +$590K +40,905 +33%
Balyasny Asset Management
12
Balyasny Asset Management
Illinois
$2.55M +$2.16M +149,477 New
Invesco
13
Invesco
Georgia
$2.2M +$732K +50,745 +65%
Northern Trust
14
Northern Trust
Illinois
$2.07M -$17.4K -1,203 -1%
BIT
15
BlackRock Institutional Trust
California
$1.77M -$44.9K -3,111 -3%
FCM
16
Farallon Capital Management
California
$1.62M – – –
OPPM
17
Opus Point Partners Management
New York
$1.2M +$1.02M +70,400 New
Mackenzie Financial
18
Mackenzie Financial
Ontario, Canada
$1.09M +$924K +64,100 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$1.04M +$68.5K +4,748 +8%
TC
20
TFS Capital
Pennsylvania
$947K -$932K -64,605 -54%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$932K +$80.7K +5,599 +11%
TCIM
22
TIAA CREF Investment Management
New York
$753K +$245 +17 +0%
TI
23
Telemetry Investments
New York
$631K +$534K +37,000 New
BIM
24
BlackRock Investment Management
Delaware
$579K -$1.66K -115 -0.3%
California Public Employees Retirement System
25
California Public Employees Retirement System
California
$443K – – –
1
2 3

STML Hedge Fund Activity: Q4 2014 in Review

62 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2014, worth a combined $130M — up 46% from $88.9M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new STML positions and 8 closed out — a net gain of 3 holders — while 19 added to existing stakes and 15 trimmed.

The largest buyer was VHCP Management, adding an estimated $4.12M. The largest seller was Artal Group, exiting entirely with an estimated $2.12M sold.

  • 62 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2014, up from 61 in Q3 2014.
  • Funds reported $130M of Stemline Therapeutics, Inc. stock for Q4 2014, up 46% quarter-over-quarter.
  • 11 funds opened new Stemline Therapeutics, Inc. positions in Q4 2014 and 8 closed out, a net change of +3 holders.
  • The largest Stemline Therapeutics, Inc. buyer in Q4 2014 was VHCP Management, an estimated $4.12M added.
  • The largest Stemline Therapeutics, Inc. seller in Q4 2014 was Artal Group, an estimated $2.12M sold.

Based on aggregated 13F filings for Q4 2014.